
Statins, which help to slash cholesterol levels, do not cause cancer, a recent major study has revealed.
Statins had previously been linked to an increased risk of developing tumors.
Advertisement
However, the latest research conducted by statins expert Professor Rory Collin of Oxford University has dismissed any link to cancer, reports the Daily Express.
Along with a team from the University of Sydney in Australia, the researchers looked at data on 170,000 patients around the world who were given either statins or a dummy pill.
However, the rate of cancer was found the same among those taking statins as it was for those taking the placebo.
"These findings are extremely reassuring for patients," said Professor Collins, British Heart Foundation professor of medicine and epidemiology at Oxford University.
"Statins are one of the most effective known therapies for the prevention of heart attacks and strokes and this study should reassure the millions of people who are taking them worldwide," he added.
Source: ANI
Advertisement
However, the rate of cancer was found the same among those taking statins as it was for those taking the placebo.
"These findings are extremely reassuring for patients," said Professor Collins, British Heart Foundation professor of medicine and epidemiology at Oxford University.
"Statins are one of the most effective known therapies for the prevention of heart attacks and strokes and this study should reassure the millions of people who are taking them worldwide," he added.
Source: ANI
Advertisement
Advertisement
|
Advertisement
Recommended Reading
Latest Drug News

Addressing the unmet needs of Parkinson's Disease by providing disease-modifying therapies could bring about a major shift in the way that patients are treated.

Microrobots could swirl through a person's blood stream, search for targeted areas to treat for various ailments.

Supplementation with multivitamins is an inexpensive way for older adults to slow down memory loss.

Some people with an aggressive blood cancer called acute myeloid leukemia (AML) may soon have a new drug option called Ivosidenib that blocks the activity of IDH1 gene.

In case of cardiac failure where the ejection fraction is greater than 40%, sacubitril/valsartan can prove to be quite beneficial